

7. (Amended) Isolated and purified biologically active TFPI comprising an N-terminal amino acid sequence as shown in SEQ ID NO: 7, wherein the biologically active TFPI has an inhibitory concentration of at least 1 µg/ml in a prothrombin clotting assay, according to a method comprising:

made by? could be made by?

a
sub
m
transforming yeast cells with a vehicle, said vehicle comprising a first nucleotide sequence encoding TFPI, wherein the N-terminal amino acid sequence of the TFPI is SEQ ID NO: 7, said first nucleotide sequence being immediately preceded in frame by a second nucleotide sequence encoding ubiquitin, the first and second nucleotide sequences together encoding a fusion protein;

incubating the transformed yeast cells under conditions favorable for production of the TFPI, wherein the TFPI is retained within the yeast cell;

preparing an insoluble fraction of the transformed yeast cells containing the TFPI; and

recovering the TFPI from the insoluble fraction.

IN THE SPECIFICATION

Please add the following new paragraph after the title of the invention, at line 2.

a2
This application is a continuation of U.S. Serial Number 08/854,764, filed May 12, 1997, now U.S. Patent 6,103,500, which is a continuation of U.S. Serial Number 08/286,530, filed August 5, 1994, abandoned.

Please replace the paragraph at page 17, lines 24-28 with the following paragraph.

a3
N-terminal sequencing of the product recovered by this method gave the following correct sequence: